RxDoctor Payments Data

Darren Reed, DO

Family Medicine · Lafayette, INNPI 1629277389

Payments from drug & device makers

$439in general payments, 2019–2025

Across 23 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$116
  • Lilly USA, LLC$105
  • Novo Nordisk$97
  • Pfizer$75
  • Exact Sciences$33
  • Boston Scientific$14

What the payments were for

  • Food & beverage$439100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie6$116
Lilly USA, LLC5$105
Novo Nordisk5$97
Pfizer4$75
Exact Sciences2$33
Boston Scientific1$14

How this compares

$439 in reported general payments places this provider in the 45th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$219,699
Medicare patients
464
Services billed
3,020

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$124,737
OzempicSemaglutide59$70,936
XareltoRivaroxaban32$48,644
TrulicityDulaglutide31$41,469
MounjaroTirzepatide28$38,180
RybelsusSemaglutide21$32,712
JardianceEmpagliflozin17$15,180
Spiriva HandihalerTiotropium Bromide16$12,857
Tresiba Flextouch U-100Insulin Degludec14$10,717
SymbicortBudesonide/Formoterol Fumarate15$10,336
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$9,876
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$5,208
Omeprazole399$4,957
Atorvastatin Calcium631$4,557
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp25$4,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$75$126,167144 claims
Novo NordiskOzempic, Rybelsus$97$103,64980 claims
Lilly USA, LLCTrulicity, Mounjaro$105$79,65059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →